新京报贝壳财经讯（记者丁爽）2月25日，爱博医疗发布公告称，拟使用并购贷款及自有资金收购德美 联合（重庆）医疗科技有限公司（简称"德美医疗"）68.31%股权，交易对价为6.83亿元。 财务数据显示，2025年，德美医疗营收为2.86亿元，调整后净利润为2360.23万元。 2024年运动相关损伤植入物纳入国家带量采购范围后，德美医疗部分主营业务产品入选第四批国家高值 医用耗材集采A组。目前钛合金带线锚钉、PEEK带线锚钉、软组织固定钉等多款产品已进入集采。 校对 赵琳 针对此次收购带来的影响，爱博医疗在公告中提及，公司核心业务聚焦于生物医用材料及高端医疗器械 的研发及商业化。通过本次收购标的公司控股权，公司拟拓宽医疗健康领域布局，在研发、生产制造、 销售渠道等方面与标的公司协同，进一步提升公司业绩与股东回报水平。 爱博医疗进一步称，本次交易对价以现金方式支付，将导致公司产生一定规模的现金净流出。交易资金 部分拟来源于银行并购贷款，贷款比例预计为交易价格的70%—80%，预计将使公司合并报表层面新增 一定规模的有息负债。公司拟使用自有资金分期偿还贷款本息，预计每年将新增一定财务费用，可能对 公司利润产生一定影 ...

这份荣耀的背后，是四川省骨科医院全程专业的医疗保障，更是医院深耕运动医学、长期护航运动员的硬核实力彰显。 苏翊鸣夺得首金后与四川省骨科医院崔博医师（左）合影。（图片由医院提供） 四川在线记者 魏冯 何嘉琦 北京时间2月18日，米兰冬奥会单板滑雪男子坡面障碍技巧决赛落幕，中国队选手苏翊鸣以82.41分摘得金牌，为中国代表团拿下本届冬奥会首金，而这一天 恰逢他22岁生日。夺冠后，苏翊鸣与四川省骨科医院运动医学科崔博医师相拥而泣，喊出： "我们做到了！" 北京冬奥周期，四川省骨科医院张强副主任医师作为队医，运用郑氏伤科手法结合牵拉、物理治疗等综合方案，精准改善苏翊鸣髋关节疼痛症状，助力其以 最佳状态参赛并斩获佳绩。北京冬奥会之后，该院邓乔丹、阳海平、汤晨曦、洪桥梅、曲亭亭等多位运动医学专家持续为中国单板滑雪大跳台和坡面障碍技 巧队接续提供专业医疗保障，针对队伍训练中出现的踝关节扭伤、长期训练疲劳等共性与个性问题，依托郑氏伤科特色技术开展应急处置与常态化调理。 精准施治，赛场护航铸就荣耀 本届米兰冬奥会，四川省骨科医院崔博医师专职负责苏翊鸣的医疗保障工作，从备赛到参赛全程随队驻守。备赛阶段，苏翊鸣本就存在腰、髋、踝关 ...

Core Viewpoint - Aibo Medical announced plans to acquire at least 51% of Demai Medical, with an estimated valuation of the target company not exceeding 1 billion yuan [1] Company Summary - Demai Medical, founded in July 2016, has a registered capital of over 12.14 million yuan and is controlled by its founder and major shareholder, Li Jianbo, who holds 14.7994% of the shares [1] - The company has a strategic focus on the entire spectrum of sports health, including pre-surgery prevention, surgical treatment, and post-surgery rehabilitation, and operates as an international medical technology group [1][2] - As of the announcement date, Demai Medical has 276 authorized patents and has obtained various medical device registrations, including 34 Class III, 48 Class II, and 63 Class I medical device registration certificates [2] Industry Summary - The domestic sports medicine market is currently dominated by international brands, which hold approximately 80% market share, with major players including Stryker, Johnson & Johnson, and Arthrex [5] - The market size for sports medicine in China is projected to reach 8-10 billion yuan in 2025, with a compound annual growth rate of about 15%-20% [5] - The inclusion of sports-related injury implants in the national procurement plan in 2024 is expected to create opportunities for domestic companies to expand their market share and enhance industry influence [2] Financial Summary - As of the end of 2025, Demai Medical's total assets are projected to be 425 million yuan, with total liabilities of 160 million yuan and equity of 260 million yuan [3] - The expected revenue for 2025 is 286 million yuan, with an adjusted net profit of approximately 35.02 million yuan [3]

Core Viewpoint - Beijing Tianxing Medical Co., Ltd. is seeking to list on the Hong Kong Stock Exchange after withdrawing its application for the Sci-Tech Innovation Board in China due to market conditions and lengthy approval processes [2][3] Company Overview - Tianxing Medical, established in 2017, focuses on innovative medical devices for sports medicine, offering comprehensive clinical solutions through its four patented technology platforms [2] - The company has developed a total of 52 products, including 20 Class III medical devices, with several being the first of their kind approved for clinical use in China [4] Financial Performance - Revenue figures for Tianxing Medical from 2022 to 2025 (first five months) are as follows: 147 million, 239 million, 327 million, and 111 million RMB, with gross profits of 104 million, 177 million, 228 million, and 82 million RMB respectively [9] - The gross margin has remained above 69%, with the highest margins coming from implants and surgical devices [9] Market Position - Tianxing Medical is recognized as the largest domestic sports medicine company in China based on projected sales revenue for 2024 [10] - The company has achieved profitability consistently, although it is noted that its overall scale is relatively small [11] Revenue Structure - The majority of Tianxing Medical's revenue comes from implants, which accounted for over 70% of total revenue, raising concerns due to the impact of centralized procurement on pricing [12] - The company has seen a significant increase in overseas revenue, which grew from 0.3% of total revenue in 2022 to 18.4% in the first five months of 2025, indicating a strong growth trajectory [13][14] Future Prospects - The company plans to use funds raised from the IPO to expand production capacity, enhance research and development, and support marketing efforts [15] - The global sports medicine market is expected to grow at a rate of 6.5% annually, potentially reaching a size of $8.8 billion by 2030, positioning Tianxing Medical as a key player in this expanding market [15]

Core Viewpoint - Tianxing Medical is a rapidly advancing company in the sports medicine sector, recently submitting an IPO application to the Hong Kong Stock Exchange after a previous attempt in the STAR Market was terminated. The company faces both opportunities for growth and challenges from centralized procurement policies in the medical device industry [2][5][20]. Group 1: Company Overview - Tianxing Medical was established in 2017 and is headquartered in Beijing. The company focuses on innovative medical devices in the sports medicine field, providing solutions for soft tissue injuries and rehabilitation [7][11]. - The company has undergone significant changes in its ownership structure, with major shareholders including OrbiMed, Junlian Capital, and others. As of August 2023, the post-investment valuation was approximately 3.5 billion RMB [8][7]. - The founder and current chairman, Dong Wenxing, has a background in medical device regulation, which may provide strategic advantages in navigating the industry [9][10]. Group 2: Financial Performance - Tianxing Medical's revenue has shown consistent growth, with figures of 147 million RMB in 2022, 239 million RMB in 2023, and projected 327 million RMB in 2024. Net profits have also increased, reaching 57 million RMB in 2023 [16][17]. - The company has a diverse product matrix, with over 52 approved products and more than 35 in development. The product sales have penetrated over 3,000 hospitals in China [13][16]. - The gross profit margin has fluctuated, with a notable decline in 2024 due to the inclusion of certain products in centralized procurement programs, leading to price reductions [20][19]. Group 3: Market Position and Competition - The sports medicine market in China is still developing, with a market size of approximately 5.4 billion RMB in 2024, compared to a global market size of 6.1 billion USD. The domestic market has significant growth potential [30][33]. - Tianxing Medical holds a market share of about 6.5% in the Chinese sports medicine sector, ranking fourth among all brands and first among domestic brands [33][35]. - The company faces competition from both international players like Smith & Nephew and Johnson & Johnson, as well as domestic companies such as TeliFu and Shanghai Ligetai [33][35]. Group 4: Industry Trends and Challenges - The sports medicine industry is characterized by high concentration, with the top five players accounting for approximately 67.5% of the market share [33]. - The company is under pressure from centralized procurement policies, which may impact pricing and profitability if more products are included in such programs [20][21]. - Continuous innovation and R&D investment are crucial for maintaining competitiveness in the rapidly evolving medical device landscape [22][23].

Core Viewpoint - Beijing Tianxing Medical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, positioning itself as the largest domestic sports medicine company in China by projected sales revenue in 2024 [1][4]. Company Overview - Tianxing Medical focuses on innovative medical devices providing comprehensive clinical solutions for sports medicine, including treatment for soft tissue injuries in various joints [4]. - The company offers a diverse product matrix with 52 products, including implants, active devices, consumables, and surgical instruments, making it a leader in the domestic sports medicine market [4]. Market Growth - The sports medicine market in China is expected to grow at a compound annual growth rate (CAGR) of 14.3% from 2024 to 2030, driven by an increasing sports population, aging demographics, heightened health awareness, and rising penetration of minimally invasive surgeries [4]. Financial Performance - Tianxing Medical reported revenues of approximately RMB 146.6 million, RMB 238.5 million, RMB 327.1 million, and RMB 111.4 million for the years 2022, 2023, 2024, and the first five months of 2025, respectively [5][7]. - The net profit for the same periods was RMB 40.3 million, RMB 57.1 million, RMB 95.4 million, and RMB 32.6 million [5][7]. - The company has achieved deep market penetration, with its products entering over 1,000 hospitals by the end of 2022 and projected to exceed 3,000 by the end of 2024 [5].

Core Viewpoint - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor, as announced by the Shanghai Stock Exchange on June 6 [1] Company Overview - Tianxing Medical, established in July 2017, specializes in innovative medical devices for sports medicine, focusing on the research, production, and sales of implants, active devices, consumables, and surgical tools [2] - The company provides comprehensive clinical solutions for patients and doctors in the field of sports medicine [2] Financial Performance - Tianxing Medical's revenue has shown rapid growth, with figures of 73.01 million yuan, 148 million yuan, 241 million yuan, and 223 million yuan for the years 2021 to 2023 and the first nine months of 2024, respectively [2] - The net profit for the same periods was -110 million yuan, 40.34 million yuan, 63.58 million yuan, and 64.08 million yuan [2] - The compound annual growth rate (CAGR) of revenue from 2021 to 2023 was 81.75% [2] Market Position - The Chinese sports medicine market is projected to grow from approximately 6.09 billion yuan in 2023 to about 13.05 billion yuan by 2030, with a CAGR of around 11.5% from 2022 to 2030 [2] - In 2023, imported products held over 80% of the market share in China's sports medicine sector, with Tianxing Medical capturing about 4% of the market, ranking first among domestic companies [3] Competitive Landscape - Tianxing Medical faces significant competition from multinational companies, which have established brand recognition and extensive sales networks [3] - Compared to listed peers such as Dabo Medical, Kailitai, Weigao Orthopedics, and Chunli Medical, Tianxing Medical's revenue of 223 million yuan is relatively small, with its competitors reporting revenues of 1.529 billion yuan, 750 million yuan, 1.083 billion yuan, and 508 million yuan, respectively [4] Fundraising and Financial Concerns - The company faced market skepticism regarding the rationality of its fundraising plan, which initially aimed to raise 1.093 billion yuan, with a significant portion allocated for working capital [5] - As of September 30, 2024, Tianxing Medical's total assets were 551 million yuan, and net assets were 446 million yuan, with a debt ratio of only 19.03% [6] - The company planned to use 220 million yuan for working capital, raising questions about the necessity of this allocation given its existing cash reserves of 384 million yuan [6]

Core Viewpoint - Tianxing Medical's IPO on the Sci-Tech Innovation Board has been terminated due to the withdrawal of its sponsor, leading to the cessation of its listing review process [1] Company Overview - Tianxing Medical is an innovative medical device company specializing in sports medicine, focusing on the research, production, and sales of sports medicine implants, active devices, consumables, and surgical tools [3] - The company has established a comprehensive product matrix with 47 approved sports medicine products as of September 30, 2024, including several first domestically approved products in the implant field [3] - Tianxing Medical has obtained 20 Class III and 17 Class II medical device registration certificates, along with CE certifications for 15 products, and has received medical device registration or filing certificates from multiple countries [3] Market Position - As of 2023, Tianxing Medical holds approximately 4% of the sports medicine medical device market in China, ranking first among domestic companies [3] Financial Performance - The company reported revenues of 148 million yuan, 241 million yuan, and 223 million yuan for the years 2022 and the first three quarters of 2024, respectively, with net profits of 40.34 million yuan, 63.58 million yuan, and 64.08 million yuan [4] - A significant price drop of around 60% for its products was noted following the national centralized procurement process, which could impact the company's profitability if sales do not meet expectations [4] IPO Journey - Tianxing Medical's IPO was accepted in September 2023, with plans to raise 880 million yuan for a smart factory project, product development, and working capital [5] - The company faced inquiries during the review process but did not disclose responses before withdrawing its IPO application [5]